Clinuvel Pharmaceuticals Limited
OTC: CLVLY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Philippe Jacques Wolgen
- Employees
- 100
- Headquarters
- Melbourne, Australia
- IPO year
- 2008
- Market cap
- $357.9M
- Website
- https://www.clinuvel.com
Loading CLVLY…
Loading profile data…Frequently asked questions about CLVLY
What does Clinuvel Pharmaceuticals Limited (CLVLY) do?
Clinuvel Pharmaceuticals Limited is a biopharmaceutical firm dedicated to creating and marketing therapies for individuals worldwide grappling with genetic, metabolic, and severe medical conditions, operating across Australia, Europe, the United States, and Switzerland. Their flagship therapeutic, SCENESSE, is a systemic photoprotective medicati...
Where does CLVLY trade?
Clinuvel Pharmaceuticals Limited (CLVLY) trades on the Other OTC.
What sector is CLVLY in?
Clinuvel Pharmaceuticals Limited (CLVLY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Clinuvel Pharmaceuticals Limited?
Philippe Jacques Wolgen is the chief executive officer of Clinuvel Pharmaceuticals Limited (CLVLY).
Where is Clinuvel Pharmaceuticals Limited headquartered?
Clinuvel Pharmaceuticals Limited is headquartered in Australia.
Does CLVLY pay a dividend?
Yes — Clinuvel Pharmaceuticals Limited (CLVLY) paid a trailing twelve-month dividend of USD 0.03 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did CLVLY go public?
Clinuvel Pharmaceuticals Limited (CLVLY) completed its initial public offering in 2008.
Is CLVLY an ADR?
Yes — CLVLY is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Clinuvel Pharmaceuticals Limited reporting and dividends follow the underlying issuer.